Celera Corporation Company Profile
Celera is a healthcare business focusing on the integration of genetic testing into routine clinical care through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Celera also commercializes a wide range of molecular diagnostic products through Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer. Information about Celera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.celera.com.
News Articles
New algorithm for faster human genome sequencing
In 2001, the Human Genome Project and Celera Genomics announced that after 10 years of work at a cost of some $400 million, they had completed a draft sequence of the human genome. Today, sequencing a...
Cellmid licensees advance commercialisation of lung, bladder tests
Cellmid (ASX: CDY) licensee Quest (Celera) has validated its lung cancer test, incorporating Cellmid’s midkine technology, on the Luminex commercial platform.Luminex is widely used by pathology...
In 2001, the Human Genome Project and Celera Genomics announced that after 10 years of work at a cost of some $400 million, they had completed a draft sequence of the human genome. Today, sequencing a...
Drugs and Medications
None
PubMed Articles
The human reference genome is still incomplete and a number of gene sequences are missing from it. The approaches to uncover them, the reasons causing their absence and their functions are less explor...
Carriers of Rare Missense Variants in IFIH1 Are Protected from Psoriasis.
Testing of approximately 25,000 putative functional single-nucleotide polymorphisms (SNPs) across the human genome in a genetic association study has identified three psoriasis genes, IL12B, IL23R, an...
An algorithm for automated closure during assembly.
ABSTRACT: BACKGROUND: Finishing is the process of improving the quality and utility of draft genome sequences generated by shotgun sequencing and computational assembly. Finishing can involve targeted...
Clinical Trials
None
Companies
Celera is a healthcare business focusing on the integration of genetic testing into routine clinical care through a combination of products and services incorporating proprietary...
Celera is engaged principally in integrating high throughput technologies to create therapeutic discovery and development capabilities for internal use and for its customers and collaborators. Celera...
PE Corporation-Celera Genomics
The Celera Genomics Group is engaged principally in integrating advanced technologies to create therapeutic discovery and development capabilities for internal use and for its customers and collaborat...
MetaMorphix Inc. was formed in 1994 as a research collaboration between Genetics Institute, now a part of Wyeth (a pharmaceutical company) and the Johns Hopkins School of Medicine. The purpose of the...
Celera is a molecular diagnostics business with powerful discovery platforms dedicated to the practice of Targeted Medicine. Located in Rockville, MD and Alameda, CA, the company employs about 300 peo...
More Information about "Celera Corporation" on BioPortfolio
We have published hundreds of Celera Corporation news stories on BioPortfolio along with dozens of Celera Corporation Clinical Trials and PubMed Articles about Celera Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Celera Corporation Companies in our database. You can also find out about relevant Celera Corporation Drugs and Medications on this site too.
